Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore (Nasdaq: ECOR) announced enrollment of the first eight patients in an investigator-led study evaluating gammaCore non-invasive vagus nerve stimulation (nVNS) as an adjunctive treatment for PTSD.
The study will enroll up to 40 adults, assess outcomes over a 12-week treatment period, and run approximately 10 months. Primary endpoints are treatment-related serious adverse events and change in CAPS-5 total score at 12 weeks. electroCore is providing an educational grant and devices.
electroCore (Nasdaq: ECOR) announced on April 1, 2026 the publication of a Frontiers in Neuroscience paper reporting a post-hoc analysis of 35 patients with chronic mild traumatic brain injury (mTBI) and comorbid PTSD. The analysis found adjunctive non-invasive vagus nerve stimulation (nVNS) significantly reduced overall symptom burden across cognitive, affective, and somatic domains.
According to the company, the study examined a high-symptom-burden cohort and adds to evidence supporting the therapeutic potential of nVNS for chronic mTBI with PTSD.
electroCore (NASDAQ: ECOR) announced two executive hires and inducement equity grants effective April 2026. Seth Abrams will join as VP, Sales on April 1, 2026, and Michael Fox will join as Chief Operating Officer on April 13, 2026.
The Compensation Committee granted 30,000 RSUs to Abrams and 70,000 RSUs to Fox under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of grant and will be settled in common stock upon vesting, subject to continued employment.
electroCore (Nasdaq: ECOR) announced issuance of two new U.S. patents that expand protection for its non-invasive vagus nerve stimulation (nVNS) platforms.
The patents (U.S. Pat. No. 12,208,263 on Jan 28, 2026; U.S. Pat. No. 12,213,795 on Feb 4, 2026) broaden claims for device positioning, therapy adjustment, data storage, and remote monitoring. The company says its estate now exceeds 160 issued U.S. patents and that patent terms may extend to at least 2039, supporting exclusivity into the 2040s.
electroCore (Nasdaq: ECOR) reported record full year 2025 net sales of $32.0 million, up ~27% from $25.2 million in 2024, driven by U.S. prescription growth and a 97% rise in general wellness sales.
GAAP net loss was $14.0 million; adjusted EBITDA loss improved to $8.7 million. Total cash was $11.6 million at December 31, 2025. The company provided 2026 revenue guidance of approximately 30% growth and announced CEO Dan Goldberger will retire April 1, 2026, with Joshua Lev named interim President and Michael Fox hired as COO.
electroCore (Nasdaq: ECOR) management will participate in the 38th Annual Roth Conference March 22–24, 2026, at the Ritz-Carlton in Laguna Niguel, California. CFO Joshua Lev will host one-on-one investor meetings. Investors can schedule via their Roth representative or by emailing investors@electrocore.com.
electroCore (Nasdaq: ECOR) will report fourth quarter and full year 2025 financial results after market close on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review results and take investor questions; dial-in and webinar access details are provided.
electroCore (Nasdaq: ECOR) announced a research study with Acacia Clinics and the Vagus Nerve Society testing gammaCore Sapphire as an adjunctive treatment for PTSD symptoms.
The prospective study will enroll up to 40 adults (18–70) over an anticipated 10-month period. The primary safety measure is incidence of treatment-related significant adverse events (SAEs); the primary efficacy endpoint is change from baseline in CAPS-5 total score at 12 weeks (vs baseline/4-week run-in). Secondary outcomes include change in PCL-5 and Clinical Global Index (CGI) at 12 weeks. The study is led by Danielle DeSouza MSc, PhD, sponsored by the Vagus Nerve Society, with electroCore providing an educational grant and devices.
electroCore (Nasdaq: ECOR) reported preliminary unaudited full-year 2025 results and guidance: record revenue expected at $31.8–$32.0 million, representing ~26% growth versus 2024 ($25.2M). Fourth-quarter 2025 revenue is anticipated at $9.0–$9.2 million, about 30% growth versus Q4 2024. The company ended 2025 with approximately $11.6 million in cash, cash equivalents, and marketable securities, down from ~$13.2 million at September 30, 2025. electroCore described these figures as preliminary unaudited guidance and plans a full operational and financial update on its Q4 and FY2025 earnings call in March 2026.
electroCore (Nasdaq: ECOR) announced a peer‑reviewed study showing its TAC‑STIM™ transcutaneous vagal nerve stimulation (tVNS) device improved mood, task performance, and learning in 70 active‑duty U.S. Air Force trainees.
Key results include statistically significant reductions in distress (p<0.001), higher perceived ability (p=0.020), increased energy (p=0.002), and objective performance gains in intelligence tasks and instructor assessments (group main effect p=0.020). Findings were sustained across four days and will be presented at AHFE2025 on December 8, 2025.